PL.74 Induction of Labour with Propess®
Autor: | J Danson-Smith, J Amu, M Isdale |
---|---|
Rok vydání: | 2013 |
Předmět: |
Spontaneous vaginal delivery
medicine.medical_specialty Pregnancy Vaginal birth business.industry Obstetrics Vaginal delivery medicine.medical_treatment Failed induction Reproductive medicine Obstetrics and Gynecology General Medicine medicine.disease medicine.anatomical_structure Pediatrics Perinatology and Child Health Medicine Caesarean section business Cervix |
Zdroj: | Archives of Disease in Childhood - Fetal and Neonatal Edition. 98:A75.2-A75 |
ISSN: | 1468-2052 1359-2998 |
Popis: | Introduction Propess ® is a vaginal delivery system that consists of a non-biodegradable polymeric drug delivery device containing 10 mg dinoprostone (Prostaglandin E 2 ) dispersed throughout its matrix. Introduction in most units as a method of induction of labour is largely due to reported benefits which include effectiveness and better patient experience. Objective To evaluate the use of Propess ® for induction of labour and the pregnancy outcome of the recipients. Method A retrospective review of all induction of labour undertaken with Propess® over 4 months. Data was extracted from Euro king database unto excel for analysis. Result 66 patients, with parity not more than 3, were induced with Propess® at term. The commonest indication for induction was post maturity (74%) however 4 (6%) high risk patients were induced with Propess®. 93% of patients who achieved spontaneous vaginal delivery received single dose Propess®. Patients delivered through caesarean section had slightly bigger babies (SVD 3.666 kg: CS 3.713 kg), were more likely to receive additional agents (prostin) to ripen the cervix and syntocinon to augment labour. Overall 55 patients (83%) achieved vaginal birth (spontaneous and assisted) and 17% via emergency caesarean section. Conclusion Propess® is a cost effective agent for induction of labour as over 80% of patients achieved vaginal birth after single dose. However further studies are required to determine choice and/or dosage of additional cervical ripening agents suitable for use when single dose Propess® fails. This will help to reduce the number of caesarean sections performed for ‘failed induction’ after single dose Propess®. |
Databáze: | OpenAIRE |
Externí odkaz: |